Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. In particular, the stock is 'cheap' on EV/EBITDA.
Target Price
The average target price of NVNO is 13 and suggests 18% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell